| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5741803 | WOODWARD | Substituted thiazolidinedionle derivatives |
Apr, 2015
(9 years ago) | |
|
US5741803 (Pediatric) | WOODWARD | Substituted thiazolidinedionle derivatives |
Oct, 2015
(8 years ago) | |
| US6288095 | WOODWARD | Compounds |
Feb, 2017
(7 years ago) | |
|
US6288095 (Pediatric) | WOODWARD | Compounds |
Aug, 2017
(6 years ago) | |
| US7358366 | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Apr, 2020
(4 years ago) | |
|
US7358366 (Pediatric) | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Oct, 2020
(3 years ago) | |
Avandia is owned by Woodward.
Avandia contains Rosiglitazone Maleate.
Avandia has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Avandia are:
- US5741803
- US5741803*PED
- US6288095
- US6288095*PED
- US7358366
- US7358366*PED
Avandia was authorised for market use on 25 May, 1999.
Avandia is available in tablet;oral dosage forms.
Avandia can be used as use of avandia as monotherapy, in combination with metformin, and in combination with sulfonylureas to improve glycemic control in patients with type 2 diabetes mellitus, method of treatment of type ii diabetes.
The generics of Avandia are possible to be released after 19 October, 2020.
Drugs and Companies using ROSIGLITAZONE MALEATE ingredient
Market Authorisation Date: 25 May, 1999
Treatment: Use of avandia as monotherapy, in combination with metformin, and in combination with sulfonylureas to improve glycemic control in patients with type 2 diabetes mellitus; Method of treatment of type i...
Dosage: TABLET;ORAL
AVANDIA family patents
